Fed. Circ. Pulls Contested Line In Its Sandoz Biosimilar Ruling
The Federal Circuit said Tuesday that it is throwing out a controversial line indicating that patent infringement under the doctrine of equivalents applies only in exceptional cases....To view the full article, register now.
Already a subscriber? Click here to view full article